SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation -- Ignore unavailable to you. Want to Upgrade?

To: keokalani'nui who wrote (4914)11/9/2001 7:58:27 PM
From: Miljenko Zuanic  Read Replies (1) | Respond to of 52153
 
OT

<<Alexion data is exactly as represented by CEO. I, the English major, pushed around some numbers and I think it looks solid for what is says.>>

I am more interested in two PII MI trials. If they disappoint my prediction is that P&G will pull out. Which may be more positive, than negative. Based on their (P&G) capability to make sound decision (RE:Axokine).

Miljenko



To: keokalani'nui who wrote (4914)11/12/2001 10:43:00 AM
From: Biomaven  Read Replies (1) | Respond to of 52153
 
Wilder,

<ALXN>

Were you able to find the abstract relating to the neurocog data that is being presented at the satellite conference? They haven't talked about this at all, which leads me to believe it was not favorable.

With ALXN trading around cash it looks like a pretty good speculation to me. I agree that the abstract data is consistent with their original presentation of the data.

Peter


HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News